Compass Therapeutics, Inc. Common Stock
Here’s whether Compass Therapeutics, Inc. Common Stock (CMPX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); RSI 63 — healthy momentum range; strong 1-year return of +252.9%; 3-month momentum positive (+5.3%); rising volume confirms the move (1.35x 30d avg). Concerns: 50-day MA is falling (-2.44% over 10 days). Currently 12.8% off its 52-week high. Score: +6/7.
CMPX is in a confirmed uptrend, trading above both its 50-day ($5.70) and 200-day ($4.57) moving averages. An RSI of 63.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +252.9% compares to +35.1% for SPY (beat the market by 217.8%).